GGrantIndex
← Leaderboards

Pavel A Petukhov

University Of Illinois At Chicago

$5,330,073
Attributed
$11,079,112
Total exposure
12
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.1M · FY200625
$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,079,112 · 12

By mechanism

R21$3,596,399 · 8
UH2$3,306,742 · 1
R01$2,829,310 · 2
R33$1,346,661 · 1

Most similar at University Of Illinois At Chicago

Same institution · by research overlap

Others in their field

Top investigators on “Design

Research focus

DesignBaseInhibitor/AntagonistLigandsSmall MoleculeComputer AssistedProteinsCellsToxic EffectEnzymesStructurePharmaceutical ChemistryPharmaceutical PreparationsCytotoxicityDrug DiscoveryComplexLibrariesAnimal ModelPropertyNovel TherapeuticsLeadDrug DesignMolecularBiochemistry

Grant awards (28)

Development of novel TGR inhibitors for the treatment of schistosomiasis$767,020
R01 · FY2025 · AI · contact PI
Development of novel TGR inhibitors for the treatment of schistosomiasis$800,624
R01 · FY2024 · AI · contact PI
Discovery of novel smHDAC8 inhibitors for the treatment of schistosomiasis$230,492
R21 · FY2022 · AI · contact PI
Identification of the target of meclonazepam in schistosome worms$196,975
R21 · FY2022 · AI
Identification of preclinical drug candidates for the treatment of schistosomiasis$412,893
R33 · FY2021 · AI
Identification of the target of meclonazepam in schistosome worms$251,200
R21 · FY2021 · AI
Discovery of novel smHDAC8 inhibitors for the treatment of schistosomiasis$216,651
R21 · FY2021 · AI · contact PI
Identification of preclinical drug candidates for the treatment of schistosomiasis$443,078
R33 · FY2020 · AI
Identification of preclinical drug candidates for the treatment of schistosomiasis$490,690
R33 · FY2019 · AI
Identification of preclinical drug candidates for the treatment of schistosomiasis$169,545
R21 · FY2018 · AI
Identification of preclinical drug candidates for the treatment of schistosomiasis$222,045
R21 · FY2017 · AI
Photoreactive histone deacetylase probes for chromatin immunoprecipitation in can$233,570
R21 · FY2016 · CA · contact PI
Therapeutic Targeting of Carotid Body Chemoreflex for Sleep Disordered Breathing$1,643,080
UH2 · FY2015 · HL
Photoreactive histone deacetylase probes for chromatin immunoprecipitation in can$233,570
R21 · FY2015 · CA · contact PI
Therapeutic Targeting of Carotid Body Chemoreflex for Sleep Disordered Breathing$1,663,662
UH2 · FY2014 · HL
Photoreactive histone deacetylase probes for chromatin immunoprecipitation in can$198,879
R21 · FY2014 · CA · contact PI
Discovery of novel anti-HBV compounds targeting host factors$197,602
R21 · FY2014 · AI · contact PI
Discovery of novel anti-HBV compounds targeting host factors$222,119
R21 · FY2013 · AI · contact PI
Photoaffinity labeling probes for development of novel isoform selective HDAC inh$308,266
R01 · FY2011 · CA · contact PI
Photoaffinity labeling probes for development of novel isoform selective HDAC inh$317,800
R01 · FY2010 · CA · contact PI
Small Molecule Inhibitors of Malate Synthase against M. Tuberculosis$196,250
R21 · FY2010 · AI · contact PI
Photoaffinity labeling probes for development of novel isoform selective HDAC inh$317,800
R01 · FY2009 · CA · contact PI
Small Molecule Inhibitors of Malate Synthase against M. Tuberculosis$235,500
R21 · FY2009 · AI · contact PI
Photoaffinity labeling probes for development of novel isoform selective HDAC inh$317,800
R01 · FY2008 · CA · contact PI
Small molecule inhibitors pantothenate synthesis against M. tuberculosis$188,131
R21 · FY2007 · AI · contact PI
Tools for AD Research: Design of BACE2 Ligands$159,952
R21 · FY2007 · AG · contact PI
Small molecule inhibitors pantothenate synthesis against M. tuberculosis$232,500
R21 · FY2006 · AI · contact PI
Tools for AD Research: Design of BACE2 Ligands$211,418
R21 · FY2006 · AG · contact PI